Fig. 4. Effects of LCB 03-0110, tacrolimus, or tofacitinib on cell viability and IL-17A secretion in Th17 cells.
Isolated CD4+ T cells were activated with iTh17 conditions with LCB 03-0110, tacrolimus or tofacitinib at different concentrations (0.003, 0.01, 0.03, 0.1, 1, 3 and 9 µM). (A) Th17 cell viability was estimated using trypan blue staining. The data are shown as a ratio compared with the iTh17-stimulated group in the absence of compounds. **p < 0.01 or *p < 0.05 indicates the viability of the cells at 9 μM is significantly more than 80% for the compound (n = 4). (B) Expression levels of IL-17A in Th17 cells. The data are shown as a ratio compared with the iTh17-stimulated group in the absence of compounds. **p < 0.01, *p < 0.05 compared with the iTh17-stimulated group. The data are presented as the mean ± SD (n = 3). IL, interleukin; Th17, T helper 17.
© Korean J Physiol Pharmacol
